HER2/neu-directed therapy for biliary tract cancer

被引：0
|
作者：
Milind Javle
Chaitanya Churi
HyunSeon C. Kang
Rachna Shroff
Filip Janku
Rakesh Surapaneni
Mingxin Zuo
Christian Barrera
Humaid Alshamsi
Sunil Krishnan
Lopa Mishra
Robert A. Wolff
Ahmed O. Kaseb
Melanie B. Thomas
Abby B. Siegel
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine
[2] The University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology, Division of Diagnostic Imaging
[3] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
[4] Scott & White Clinic,Department of Radiation Oncology, Division of Radiation Oncology
[5] The University of Texas MD Anderson Cancer Center,Department of Gastroenterology
[6] The University of Texas MD Anderson Cancer Center,Departments of Medicine and Surgery
[7] Gibbs Cancer Center & Research Institute,undefined
[8] Columbia University,undefined
来源：
Journal of Hematology & Oncology | / 8卷
关键词：
Receptor; ErbB-2; Gallbladder neoplasms; Cancer of the biliary tract;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status
    Jiang, Mingxia
    Liu, Jiaxuan
    Li, Qiao
    Xu, Binghe
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (07) : 1324 - 1336
  • [42] High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
    Nuciforo, Paolo
    Thyparambil, Sheeno
    Aura, Claudia
    Garrido-Castro, Ana
    Vilaro, Marta
    Peg, Vicente
    Jimenez, Jose
    Vicario, Rocio
    Cecchi, Fabiola
    Hoos, William
    Burrows, Jon
    Hembrough, Todd
    Ferreres, Juan Carles
    Perez-Garcia, Jose
    Arribas, Joaquin
    Cortes, Javier
    Scaltriti, Maurizio
    MOLECULAR ONCOLOGY, 2016, 10 (01) : 138 - 147
  • [43] Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH
    Desmedt, Christine
    Sperinde, Jeff
    Piette, Fanny
    Huang, Weidong
    Jin, Xueguang
    Tan, Yuping
    Durbecq, Virginie
    Larsimont, Denis
    Giuliani, Rosa
    Chappey, Colombe
    Buyse, Marc
    Winslow, John
    Piccart, Martine
    Sotiriou, Christos
    Petropoulos, Christos
    Bates, Michael
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2009, 18 (01) : 22 - 29
  • [44] Clinical role of HER-2/neu expression in colorectal cancer
    Pappas, A.
    Lagoudianakis, E.
    Seretis, C.
    Tsiambas, E.
    Koronakis, N.
    Toutouzas, K.
    Katergiannakis, V.
    Manouras, A.
    JOURNAL OF BUON, 2013, 18 (01): : 98 - 104
  • [45] HER-2/neu expression in primary and metastatic breast cancer
    Lower, Elyse E.
    Glass, Eleanor
    Blau, Robbin
    Harman, Stacy
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (02) : 301 - 306
  • [46] Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu
    Shiu, Li Yen
    Liang, Chia Hua
    Chang, Li Ching
    Sheu, Hamm Ming
    Tsai, Eing Mei
    Kuo, Kou Wha
    BIOSCIENCE REPORTS, 2009, 29 (01) : 35 - 45
  • [47] MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer
    Bitencourt, Almir G., V
    Gibbs, Peter
    Saccarelli, Carolina Rossi
    Daimiel, Isaac
    Lo Gullo, Roberto
    Fox, Michael J.
    Thakur, Sunitha
    Pinker, Katja
    Morris, Elizabeth A.
    Morrow, Monica
    Jochelson, Maxine S.
    EBIOMEDICINE, 2020, 61
  • [48] Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
    Rakha, Emad A.
    Miligy, Islam M.
    Quinn, Cecily M.
    Provenzano, Elena
    Shaaban, Abeer M.
    Marchio, Caterina
    Toss, Michael S.
    Gallagy, Grace
    Murray, Ciara
    Walshe, Janice
    Katayama, Ayaka
    Eldib, Karim
    Badr, Nahla
    Tanchel, Bruce
    Millican-Slater, Rebecca
    Purdie, Colin
    Purnell, Dave
    Pinder, Sarah E.
    Ellis, Ian O.
    Lee, Andrew H. S.
    BRITISH JOURNAL OF CANCER, 2021, 124 (11) : 1836 - 1842
  • [49] Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer
    Aurilio, Gaetano
    Sandri, Maria Teresa
    Pruneri, Giancarlo
    Zorzino, Laura
    Botteri, Edoardo
    Munzone, Elisabetta
    Adamoli, Laura
    Facchi, Giuseppina
    Cullura, Daniela
    Verri, Elena
    Rocca, Maria Cossu
    Zurrida, Stefano
    Iacovelli, Roberto
    Nole, Franco
    FUTURE ONCOLOGY, 2016, 12 (17) : 2001 - 2008
  • [50] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
12345